<p>在過去三個月中，21 位分析師分享了他們對 Kymera Therapeutics（納斯達克：KYMR）的評估，展現出從看漲到看跌的多樣化前景。</p>
<p>下表提供了他們最近評級的快速概覽，突顯了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">10</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師對 12 個月價格目標的評估提供了額外的見解，顯示出平均目標為 120.05 美元，最高預估為 138.00 美元，最低預估為 80.00 美元。觀察到 44.97% 的增長，目前的平均值已從之前的 82.81 美元上升。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770127235_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770127235_0.png"/></p>
<h2>分析師評級探討：深入概述</h2>
<p>對金融專家如何看待 Kymera Therapeutics 的全面審查源於最近的分析師行動。以下是關鍵分析師、他們最近的評估以及評級和價格目標調整的詳細總結。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>維持</td>
<td>買入</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>Barclays</td>
<td>上調</td>
<td>超配</td>
<td>$133.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>維持</td>
<td>買入</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Kalpit Patel</td>
<td>B. Riley Securities</td>
<td>上調</td>
<td>買入</td>
<td>$117.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超配</td>
<td>$103.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>上調</td>
<td>超配</td>
<td>$110.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Mizuho</td>
<td>上調</td>
<td>超配</td>
<td>$120.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>上調</td>
<td>超配</td>
<td>$125.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Kelly Shi</td>
<td>Jefferies</td>
<td>上調</td>
<td>買入</td>
<td>$122.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>上調</td>
<td>買入</td>
<td>$110.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>上調</td>
<td>超配</td>
<td>$116.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>上調</td>
<td>買入</td>
<td>$116.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>上調</td>
<td>超配</td>
<td>$120.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>James Quigley</td>
<td>Morgan Stanley</td>
<td>上調</td>
<td>超配</td>
<td>$127.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>Barclays</td>
<td>上調</td>
<td>超配</td>
<td>$119.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>上調</td>
<td>超配</td>
<td>$125.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>上調</td>
<td>買入</td>
<td>$134.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Faisal Khurshid</td>
<td>Leerink Partners</td>
<td>上調</td>
<td>超配</td>
<td>$118.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>上調</td>
<td>買入</td>
<td>$112.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>上調</td>
<td>買入</td>
<td>$138.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>上調</td>
<td>買入</td>
<td>$80.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師根據不斷變化的市場條件和公司表現頻繁更新他們的建議。無論是 ‘維持’、‘上調’ 還是 ‘下調’，都反映了他們對 Kymera Therapeutics 最近發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析師對股票進行定性評估，範圍從 ‘超配’ 到 ‘低配’。這些評級傳達了分析師對 Kymera Therapeutics 相對於更廣泛市場的相對錶現的預期。</li>
<li><strong>價格目標：</strong> 理解預測，分析師提供 Kymera Therapeutics 未來價值的估計。檢查當前和之前的目標提供了分析師預期變化的見解。</li>
</ul>
<p>將這些分析師評估與關鍵財務指標結合起來，可以提供 Kymera Therapeutics 市場地位的全面概述。保持信息靈通，並在我們的評級表的幫助下做出明智的決策。</p>
<p>隨時瞭解 Kymera Therapeutics 的分析師評級。</p>
<h2>關於 Kymera Therapeutics</h2>
<p>Kymera Therapeutics Inc 是一家臨牀階段的生物製藥公司，致力於通過開發差異化藥物來重新定義人類疾病的治療，解決健康問題並顯著改善患者的生活。它致力於採用新技術來解決已知病因生物學的靶點，但尚未被藥物化，或藥物化不足，通常基於現有技術的侷限性。其方法旨在以疾病無關的方式發現和開發新一代藥物。其產品管線包括 STAT6、TYK2 和 IRAK4。</p>
<h3>理解數字：Kymera Therapeutics 的財務狀況</h3>
<p><strong>市值視角：</strong> 該公司的市值低於行業平均水平，表明其相對於同行的規模相對較小。這種定位可能受到感知增長潛力或運營規模等因素的影響。</p>
<p><strong>負面收入趨勢：</strong> 檢查 Kymera Therapeutics 在過去 3 個月的財務狀況顯示出挑戰。截至 2025 年 9 月 30 日，該公司經歷了約 <strong>-26.12%</strong> 的收入增長下降，反映出頂線收益的減少。與醫療保健行業的其他公司相比，該公司的增長率低於同行的平均水平。</p>
<p><strong>淨利潤率：</strong> Kymera Therapeutics 的淨利潤率低於行業平均水平，表明在實現強勁盈利能力方面面臨挑戰。其淨利潤率為 <strong>-2973.05%</strong>，公司可能在有效成本管理方面面臨困難。</p>
<p><strong>股本回報率 (ROE)：</strong> Kymera Therapeutics 的 ROE 低於行業平均水平，表明在有效利用股本方面面臨挑戰。該公司的 ROE 為 <strong>-8.57%，</strong> 可能在為股東創造最佳回報方面遇到困難。</p>
<p><strong>資產回報率 (ROA)：</strong> Kymera Therapeutics 的 ROA 低於行業平均水平，表明在有效利用資產方面面臨挑戰。該公司的 ROA 為 <strong>-7.36%，</strong> 可能在從其資產中產生最佳回報方面遇到困難。</p>
<p><strong>債務管理：</strong> Kymera Therapeutics 的債務與股本比率為 <strong>0.09，</strong> 低於平均水平，表明其採取了謹慎的財務策略，顯示出對債務管理的平衡態度。</p>
<h2>分析師評級的核心：每位投資者應知曉的事項</h2>
<p>Benzinga 跟蹤 150 家分析師公司並報告其股票預期。分析師通常通過預測公司未來的盈利能力，通常是未來五年，以及該公司收入來源的風險或可預測性來得出結論。</p>
<p>分析師參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈他們對股票的評級。分析師通常每季度對每隻股票進行一次評級，或在公司有重大更新時進行評級。</p>
<p>除了他們的評估外，一些分析師還通過提供關鍵指標的預測，如收益、收入和增長預期，來擴展他們的見解。這些補充信息為交易者提供了進一步的指導。必須認識到，儘管他們是專業人士，分析師也是人，只能根據他們的信念提供預測。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>

動態生物技術與基因組 ETF - Invesco

醫療業 ETF - Vanguard

生物科技 ETF - VanEck Vectors

<p>Kymera Therapeutics（納斯達克代碼：KYMR）在過去三個月內獲得了 21 位分析師的褒貶不一的評價，平均 12 個月目標價為 120.05 美元，比之前的目標上漲了 44.97%。最近的評級顯示出向看漲情緒的轉變，多位分析師顯著提高了他們的目標價。然而，該公司面臨財務挑戰，包括收入增長下降 26.12% 和淨利潤率為-2973.05%。儘管面臨這些困難，Kymera 仍保持謹慎的債務管理策略，債務與股本比率低至 0.09</p>

<p>During the last three months, 21 analysts shared their evaluations of Kymera Therapeutics (NASDAQ: KYMR), revealing diverse outlooks from bullish to bearish.</p>
<div class="lb-trans"><p>在過去三個月中，21 位分析師分享了他們對 Kymera Therapeutics（納斯達克：KYMR）的評估，展現出從看漲到看跌的多樣化前景。</p>
</div><p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他們最近評級的快速概覽，突顯了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">10</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">10</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $120.05, with a high estimate of $138.00 and a low estimate of $80.00. Observing a 44.97% increase, the current average has risen from the previous average price target of $82.81.</p>
<div class="lb-trans"><p>分析師對 12 個月價格目標的評估提供了額外的見解，顯示出平均目標為 120.05 美元，最高預估為 138.00 美元，最低預估為 80.00 美元。觀察到 44.97% 的增長，目前的平均值已從之前的 82.81 美元上升。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770127235_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1770127235_0.png"/></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<div class="lb-trans"><h2>分析師評級探討：深入概述</h2>
</div><p>A comprehensive examination of how financial experts perceive Kymera Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>對金融專家如何看待 Kymera Therapeutics 的全面審查源於最近的分析師行動。以下是關鍵分析師、他們最近的評估以及評級和價格目標調整的詳細總結。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>Maintains</td>
<td>Buy</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>Maintains</td>
<td>Buy</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Kalpit Patel</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$117.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Kelly Shi</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$122.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$116.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$116.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>James Quigley</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$127.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$119.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$134.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Faisal Khurshid</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$118.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>維持</td>
<td>買入</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>Barclays</td>
<td>上調</td>
<td>超配</td>
<td>$133.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>維持</td>
<td>買入</td>
<td>$138.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Kalpit Patel</td>
<td>B. Riley Securities</td>
<td>上調</td>
<td>買入</td>
<td>$117.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超配</td>
<td>$103.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>上調</td>
<td>超配</td>
<td>$110.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Mizuho</td>
<td>上調</td>
<td>超配</td>
<td>$120.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>上調</td>
<td>超配</td>
<td>$125.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Kelly Shi</td>
<td>Jefferies</td>
<td>上調</td>
<td>買入</td>
<td>$122.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>上調</td>
<td>買入</td>
<td>$110.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>上調</td>
<td>超配</td>
<td>$116.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>上調</td>
<td>買入</td>
<td>$116.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>上調</td>
<td>超配</td>
<td>$120.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>James Quigley</td>
<td>Morgan Stanley</td>
<td>上調</td>
<td>超配</td>
<td>$127.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>Barclays</td>
<td>上調</td>
<td>超配</td>
<td>$119.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>上調</td>
<td>超配</td>
<td>$125.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>上調</td>
<td>買入</td>
<td>$134.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Faisal Khurshid</td>
<td>Leerink Partners</td>
<td>上調</td>
<td>超配</td>
<td>$118.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>上調</td>
<td>買入</td>
<td>$112.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Jeet Mukherjee</td>
<td>BTIG</td>
<td>上調</td>
<td>買入</td>
<td>$138.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>上調</td>
<td>買入</td>
<td>$80.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kymera Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Kymera Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Kymera Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師根據不斷變化的市場條件和公司表現頻繁更新他們的建議。無論是 ‘維持’、‘上調’ 還是 ‘下調’，都反映了他們對 Kymera Therapeutics 最近發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 分析師對股票進行定性評估，範圍從 ‘超配’ 到 ‘低配’。這些評級傳達了分析師對 Kymera Therapeutics 相對於更廣泛市場的相對錶現的預期。</li>
<li><strong>價格目標：</strong> 理解預測，分析師提供 Kymera Therapeutics 未來價值的估計。檢查當前和之前的目標提供了分析師預期變化的見解。</li>
</ul>
</div><p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Kymera Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<div class="lb-trans"><p>將這些分析師評估與關鍵財務指標結合起來，可以提供 Kymera Therapeutics 市場地位的全面概述。保持信息靈通，並在我們的評級表的幫助下做出明智的決策。</p>
</div><p>Stay up to date on Kymera Therapeutics analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Kymera Therapeutics 的分析師評級。</p>
</div><h2>About Kymera Therapeutics</h2>
<div class="lb-trans"><h2>關於 Kymera Therapeutics</h2>
</div><p>Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.</p>
<div class="lb-trans"><p>Kymera Therapeutics Inc 是一家臨牀階段的生物製藥公司，致力於通過開發差異化藥物來重新定義人類疾病的治療，解決健康問題並顯著改善患者的生活。它致力於採用新技術來解決已知病因生物學的靶點，但尚未被藥物化，或藥物化不足，通常基於現有技術的侷限性。其方法旨在以疾病無關的方式發現和開發新一代藥物。其產品管線包括 STAT6、TYK2 和 IRAK4。</p>
</div><h3>Understanding the Numbers: Kymera Therapeutics's Finances</h3>
<div class="lb-trans"><h3>理解數字：Kymera Therapeutics 的財務狀況</h3>
</div><p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值視角：</strong> 該公司的市值低於行業平均水平，表明其相對於同行的規模相對較小。這種定位可能受到感知增長潛力或運營規模等因素的影響。</p>
</div><p><strong>Negative Revenue Trend:</strong> Examining Kymera Therapeutics's financials over 3M reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately <strong>-26.12%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<div class="lb-trans"><p><strong>負面收入趨勢：</strong> 檢查 Kymera Therapeutics 在過去 3 個月的財務狀況顯示出挑戰。截至 2025 年 9 月 30 日，該公司經歷了約 <strong>-26.12%</strong> 的收入增長下降，反映出頂線收益的減少。與醫療保健行業的其他公司相比，該公司的增長率低於同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Kymera Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-2973.05%,</strong> the company may face hurdles in effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Kymera Therapeutics 的淨利潤率低於行業平均水平，表明在實現強勁盈利能力方面面臨挑戰。其淨利潤率為 <strong>-2973.05%</strong>，公司可能在有效成本管理方面面臨困難。</p>
</div><p><strong>Return on Equity (ROE):</strong> Kymera Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-8.57%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<div class="lb-trans"><p><strong>股本回報率 (ROE)：</strong> Kymera Therapeutics 的 ROE 低於行業平均水平，表明在有效利用股本方面面臨挑戰。該公司的 ROE 為 <strong>-8.57%，</strong> 可能在為股東創造最佳回報方面遇到困難。</p>
</div><p><strong>Return on Assets (ROA):</strong> Kymera Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-7.36%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率 (ROA)：</strong> Kymera Therapeutics 的 ROA 低於行業平均水平，表明在有效利用資產方面面臨挑戰。該公司的 ROA 為 <strong>-7.36%，</strong> 可能在從其資產中產生最佳回報方面遇到困難。</p>
</div><p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.09</strong>, Kymera Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Kymera Therapeutics 的債務與股本比率為 <strong>0.09，</strong> 低於平均水平，表明其採取了謹慎的財務策略，顯示出對債務管理的平衡態度。</p>
</div><h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<div class="lb-trans"><h2>分析師評級的核心：每位投資者應知曉的事項</h2>
</div><p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<div class="lb-trans"><p>Benzinga 跟蹤 150 家分析師公司並報告其股票預期。分析師通常通過預測公司未來的盈利能力，通常是未來五年，以及該公司收入來源的風險或可預測性來得出結論。</p>
</div><p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<div class="lb-trans"><p>分析師參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈他們對股票的評級。分析師通常每季度對每隻股票進行一次評級，或在公司有重大更新時進行評級。</p>
</div><p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<div class="lb-trans"><p>除了他們的評估外，一些分析師還通過提供關鍵指標的預測，如收益、收入和增長預期，來擴展他們的見解。這些補充信息為交易者提供了進一步的指導。必須認識到，儘管他們是專業人士，分析師也是人，只能根據他們的信念提供預測。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>
</div>

深入分析 Kymera Therapeutics 股票：分析師觀點（21 個評級）